Published 4 days ago • loading... • Updated 4 days ago

Viatris to Make $1.65B Pacira Acquisition, Adding to Momentum in Pain

Viatris, a generics and branded medicines maker, is buying into non-opioid pain drugs with a cash acquisition of commercial-stage Pacira BioSciences. The Thursday morning deal, valued at $1.65 billion, follows a ...

7 Articles

Globo

Lean Right

Viatris Buys Pacira BioSciences for $1.65 Bi to Strengthen Portfolio of Pain Treatment

Viatris has concluded an agreement to purchase Pacira BioSciences pain medicine manufacturer for $1.65 billion, in a transaction that expands the healthcare company's drug portfolio. Exclusive material for subscribers. To have full access, access the material link and register.

4 days ago·Rio de Janeiro, Brazil

Read Full Article

The Motley Fool

Lean Left

Why Pacira BioSciences Skyrocketed Today

The specialty pharmaceutical company is being acquired.

4 days ago·Alexandria, United States

Read Full Article

endpoints.news

Viatris to make $1.65B Pacira acquisition, adding to momentum in pain

4 days ago

Read Full Article

investorideas.com

Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News

Pacira BioSciences (Nasdaq: PCRX) hits a 52 week high after Viatris agrees to acquire the non-opioid pain therapy company for $36.50 per share in cash.

4 days ago

Read Full Article

BizToc

Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly

Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing. The post Pacira Biosciences…

4 days ago

Read Full Article